In a randomized phase 2 trial in patients with acute coronary syndrome and high levels of the inflammation biomarker C-reactive protein, treatment with low-dose interleukin-2 increased the numbers of regulatory T cells and reduced arterial inflammation, compared to placebo.
- Rouchelle S. Sriranjan-Rothwell
- Tian X. Zhao
- Leanne Masters